Valirx (VAL)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

3.55p
   
  • Change Today:
    -0.30p
  • 52 Week High: 14.13
  • 52 Week Low: 3.50
  • Currency: UK Pounds
  • Shares Issued: 132.35m
  • Volume: 888,756
  • Market Cap: £4.70m
  • RiskGrade: 435

ValiRx signs letter of intent in a bid to fund VAL401

By Josh White

Date: Tuesday 14 Jan 2020

LONDON (ShareCast) - (Sharecast News) - Clinical-stage biotechnology company ValiRx updated the market on its subsidiary joint venture, ValiSeek, and its cancer therapeutic, VAL401 on Tuesday.
The AIM-traded firm said ValiSeek and its own joint venture partner, Tangent Reprofiling, had entered into a letter of intent with Black Cat Bio, which is a newly-incorporated special purpose vehicle to raise up to £5m towards commercialising VAL401, in order to progress it through the next clinical trial.

It said Black Cat Bio had entered into, and would fund, a service agreement with Zenith Partners - a private investment, corporate advisory and business transformation enterprise, to source the funding.

ValiSeek currently had a worldwide exclusive licence granted from Tangent to progress VAL401 to commercialisation.

ValiRx said ValiSeek is a 55.5% subsidiary joint venture, with the objective to develop VAL401 in the treatment of late-stage non-small cell lung cancer and potentially other indications.

The letter of intent provided that, subject to Black Cat raising a minimum, "commercially sensitive" amount, ValiSeek would revoke its license for the VAL401 patent portfolio and Tangent would execute a new intellectual property licence with Black Cat, with Black Cat being responsible for funding and executing future clinical development of VAL401.

It was proposed, subject to a successful fund raise, that ValiSeek would enter into an agreement with its shareholders to undertake a corporate reorganisation, whereby existing shareholders in ValiSeek would become shareholders in Black Cat.

Thus, following any reorganisation, ValiRx said it would hold a proportional shareholding directly in Black Cat, and would benefit from future commercial upside.

Black Cat would use the co-financing agreements outlined in the letters of Intent announced on 26 March, in order to deliver the clinical trial in an effective and cost efficient manner.

ValiRx said VAL401 is the reformulation of a generic drug that had more than 20 years of clinical use for the treatment of a chronic non-oncology disease in an oral capsule.

It said the re-formulation allowed the drug to access previously unexploited anti-cancer activity.

VAL401 had completed a clinical phase 2 trial for the treatment of late-stage non-small cell lung cancer, with data from the completed trial indicating a palliative effect and an improvement of quality of life in the patients treated.

"I am pleased to be able to announce that ValiSeek has come to an agreement with Black Cat to secure the future development of VAL401, to the advantage of all parties," said chief executive officer Dr Satu Vainikka.

At 1432 GMT, shares in ValiRx were down 6.76% at 0.1p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Valirx Market Data

Currency UK Pounds
Share Price 3.55p
Change Today -0.30p
% Change -7.79 %
52 Week High 14.13
52 Week Low 3.50
Volume 888,756
Shares Issued 132.35m
Market Cap £4.70m
RiskGrade 435

Valirx Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
23.54% below the market average23.54% below the market average23.54% below the market average23.54% below the market average23.54% below the market average
7.41% above the sector average7.41% above the sector average7.41% above the sector average7.41% above the sector average7.41% above the sector average
Price Trend
89.26% below the market average89.26% below the market average89.26% below the market average89.26% below the market average89.26% below the market average
64.91% below the sector average64.91% below the sector average64.91% below the sector average64.91% below the sector average64.91% below the sector average
Income Not Available
Growth Not Available

Valirx Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
16:19 20,000 @ 3.59p
16:15 13,380 @ 3.55p
16:05 36,000 @ 3.55p
16:02 60,340 @ 3.51p
16:01 250,000 @ 3.59p

Valirx Key Personnel

CFO Gerald Desler
CEO Suzanne Dilly

Top of Page